KEWALRAMANI RESHMA 1735944 Data last updated 2024-05-14 07:02:16 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-18 | 2023-07-17 | 2023-07-17 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 7828.0 | 6.18 | 0.3 | 355.0 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 118906.0 | 257.55 (VRTX) |
| 2023-11-15 | 2023-11-13 | 2023-11-13 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 5097.0 | 4.29 | 0.2 | 377.0 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 113809.0 | 257.68 (VRTX) |
| 2023-12-15 | 2023-12-13 | 2023-12-13 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 5098.0 | 4.48 | 0.2 | 397.0 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 108711.0 | 257.68 (VRTX) |
| 2023-12-19 | 2023-12-15 | 2023-12-15 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 17135.0 | 13.62 | 0.66 | 407.0 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code S | 108711.0 | 257.68 (VRTX) |
| 2023-12-19 | 2023-12-15 | 2023-12-15 | 4 | Kewalramani Reshma | CEO & PRESIDENT | acq | 17135.0 | 13.62 | 0.66 | 181.83 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code M | 125846.0
|
257.68 (VRTX) |
| 2024-02-08 | 2024-02-06 | 2024-02-06 to 2024-02-07 | 4 | Kewalramani Reshma | CEO & PRESIDENT | acq | 61815.0 | 36.25 | 2.4 | 0.0 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code A | 170526.0
|
257.68 (VRTX) |
| 2024-02-13 | 2024-02-09 | 2024-02-09 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 8255.0 | 4.84 | 0.32 | 422.74 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 162271.0 | 257.68 (VRTX) |
| 2024-02-21 | 2024-02-16 | 2024-02-16 to 2024-02-20 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 16378.0 | 10.09 | 0.63 | 422.54 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 145893.0
|
258.31 (VRTX) |
| 2024-02-27 | 2024-02-23 | 2024-02-23 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 9386.0 | 6.43 | 0.36 | 431.79 | Direct | Common Stock | VERTEX PHARMACEUTICALS INC / MA | code F | 136507.0 | 258.31 (VRTX) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-21 | 2023-06-16 | 2023-06-16 | 4 | Kewalramani Reshma | DIRECTOR | acq | 105263.0 | 100.0 | 0.66 | 0.0 | Direct | Restricted Stock Units | GINKGO BIOWORKS HOLDINGS, INC. | code A | 105263.0 | 1585.29 (DNA) |
| 2023-06-21 | 2023-06-16 | 2023-06-16 | 4 | Kewalramani Reshma | DIRECTOR | acq | 139860.0 | 100.0 | 0.88 | 1.9 | Direct | Stock Option | GINKGO BIOWORKS HOLDINGS, INC. | code A | 139860.0 | 1585.29 (DNA) |
| 2023-12-19 | 2023-12-15 | 2023-12-15 | 4 | Kewalramani Reshma | CEO & PRESIDENT | dsp | 17135.0 | 91.63 | 0.66 | 181.83 | Direct | Stock Option (Right To Buy) | VERTEX PHARMACEUTICALS INC / MA | code M | 1565.0
|
257.68 (VRTX) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)